Wyeth calls for “truth” over HRT therapy

Wyeth has issued a petition to the US Food and Drink Administration (FDA) calling for increased regulation regarding customised hormone replacement therapy (HRT).

The pharmaceutical and consumer healthcare company states that compounding pharmacies’ practice of revising dosages and eliminating the use off non-active ingredients and preservatives could be producing a “serious health risk” for women who use this treatment.

Wyeth claims that pharmacies are providing treatment, which can present serious health risks to women, without informing them of the potential dangers associated with it.

Candace Steel, a spokesperson for Wyeth, said: “We filed our petition so that we can ensure that women who received these bio-identical hormones also receive truthful information about the risks of therapy.”

In response to the petition, over 27,000 women have submitted comments to the FDA, reports the Associated Press.

Wyeth states that it has been active in the women’s health sector for over 60 years, providing both postmenopausal hormone therapies and oral contraceptives and invests $130 million in its Women’s Health Reasearch Institute, which it claims is only facility researching women’s health issues within the pharmaceutical industry.

© Adfero Ltd